Evaluation of Belzutifan in Patients with Tumors Associated with Von Hippel-Lindau Disease: A Retrospective Analysis from a Single Center - Scorecard - MDSpire
Advertisement
Evaluation of Belzutifan in Patients with Tumors Associated with Von Hippel-Lindau Disease: A Retrospective Analysis from a Single Center
Clinical Scorecard: Evaluation of Belzutifan in Patients with Tumors Associated with Von Hippel-Lindau Disease: A Retrospective Analysis from a Single Center
At a Glance
Category
Detail
Condition
Von Hippel-Lindau (VHL) disease, a multisystemic tumor predisposition syndrome with benign and malignant tumors including RCC, CNS and retinal hemangioblastomas, pheochromocytomas, paragangliomas, and neuroendocrine tumors
Key Mechanisms
Belzutifan is an oral small molecule inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α) that disrupts HIF transcription complex formation, preventing downstream oncogenic signaling
Target Population
Adult patients with clinically or genetically confirmed VHL disease with advanced organ manifestations requiring timely intervention
Care Setting
Multidisciplinary VHL center with collaboration among specialists; treatment administered off-label with insurance approval and monitored through regular clinical and laboratory assessments
Key Highlights
VHL disease has 100% lifetime penetrance by age 75 with tumors causing morbidity and mortality primarily from CNS hemangioblastomas, RCC, and neuroendocrine tumors
Belzutifan received FDA approval in 2021 for VHL-associated tumors but was used off-label in Germany until 2025, mainly in patients where surgery or other treatments risked organ function loss
Treatment decisions were individualized by a multidisciplinary team considering tumor burden, prior interventions, and organ function, with belzutifan as a last-line, organ-preserving therapy
Guideline-Based Recommendations
Diagnosis
Clinical or genetic confirmation of VHL disease
Annual surveillance with MRI of abdomen and CNS, plasma metanephrines, and eye examinations
Management
Primary management includes surveillance and surgical resection or ablation of tumors
Belzutifan indicated for advanced VHL-associated tumors where conventional treatments risk critical organ function loss or are ineffective
Off-label use requires multidisciplinary assessment and insurance approval
Monitoring & Follow-up
Clinical evaluations every three months at specialized VHL center
Biweekly laboratory monitoring including blood counts and liver enzymes (AST, ALT, bilirubin, INR) by primary care physicians
Risks
Potential worsening of organ function with repeated surgeries in advanced disease
Limited data on safety and efficacy outside clinical trials prior to marketing authorization
High prescription costs and need for insurance approval for off-label use
Patient & Prescribing Data
Adults with advanced VHL-associated tumors at high risk of organ function loss from standard treatments
Belzutifan administered at 80–120 mg daily dosage; used as last-line therapy to preserve organ function when surgery or chemotherapy is contraindicated or ineffective
Clinical Best Practices
Use multidisciplinary team assessment to individualize treatment decisions considering tumor burden, prior therapies, and organ function
Implement regular surveillance with imaging and laboratory tests before and during belzutifan treatment
Consider belzutifan as an organ-preserving option in advanced VHL disease when conventional therapies pose high risks
Obtain informed consent and insurance approval for off-label belzutifan use
Monitor patients closely for adverse effects and treatment response with scheduled clinical and laboratory evaluations
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
